Overview

Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The cognitive impairment of Parkinson's disease is non amnestic, which is characterized by working memory impairment and executive dysfunction. The current drug therapy (such as levodopa, dopamine receptor agonists) and surgical treatment (such as deep brain electrical stimulation, thalamic lesion) not only can not effectively alleviate cognitive impairment, but also may aggravate cognitive and speech behavior abnormalities. This project will explore how dopamine regulates temporal working memory in human research by combining drug intervention, neuroimaging and cognitive tasks.
Phase:
Phase 4
Details
Lead Sponsor:
Peking University Third Hospital
Collaborator:
Chinese Academy of Sciences
Treatments:
Benserazide, levodopa drug combination